Social Media Ideas for Fda Fast Track Designation

FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer

From: .onclive.com The FDA has granted fast track designation to ETX-19477 for the treatment of adult patients with BRCA-mutated, hormone receptor (HR)–positive, HER2-negative unre...

<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>

FDA launches pilot program to speed up early US drug research

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicin...

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli]]>

<![CDATA[FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer]]>

FDA Opens Applications for New Pilot to Shorten Drug Approval Times: What Sponsors Need to Know

Earlier this month, FDA opened applications for a new Expedited Investigational New Drug (IND) Pilot Program (the “Program”), an initiative launched under HHS Operation TrialBlazer...

Nutromics Nabs FDA Breakthrough Status for Antibiotic Monitoring Patch

Nutromics earned FDA breakthrough device designation for its wearable patch that tracks vancomycin levels in real time. The device aims to replace the periodic blood draws currentl...

Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrat...

<![CDATA[FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Me...

vTv Therapeutics stock jumps on FDA orphan drug status

FDA Grants Accelerated Approval of Advanced Breast Cancer Treatment, Etcamah (Camizestrant)

From: crf.org The U.S. Food & Drug Administration (FDA) granted accelerated approval to Etcamah (camizestrant), in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib...

First Tracks climbs on ‘impressive’ celiac study data

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potent...

<![CDATA[FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A]]>

FDA approves breakthrough cancer drug months ahead of schedule: ‘Unprecedented results’

The FDA approved the medication more than six months ahead of schedule after trials showed it nearly doubled median survival to 13.2 months versus 6.7 months with chemotherapy.

<![CDATA[FDA Launches Rare Disease Framework Initiative ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.]]>

<![CDATA[FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults ]]>

<![CDATA[What Would a Category One Designation Mean for Peptides?]]>

FDA grants priority review to ‘high-efficacy’ drug for 2 types of MS

The U.S. Food and Drug Administration (FDA) has agreed to review an application from Roche seeking approval of its BTK inhibitor fenebrutinib as a treatment for relapsing forms of...

<![CDATA[FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease]]>

<![CDATA[FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy ]...

FDA starts review of Roche’s multiple sclerosis pill

The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

<![CDATA[FDA Approves Welireg Plus Lenvima for Previously Treated Adult Patients With ccRCC]]>

<![CDATA[FDA Approves Tecentriq for Stage III dMMR Colon Cancer]]>